secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-281980
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Q1 net loss $5.1M, cash $16.5M; OPMD NH study screening starts Nov 2022
-------------------------------------------------------------------------------

- Net loss of $5.1M ($0.47 loss per share) for fiscal Q1 ended Sep 30, 2022.
- Cash and cash equivalents of $16.5M as of Sep 30, 2022, up from $4.1M at Jun 30.
- OPMD Natural History Study IRB approval received; subject screening begins Nov 2022 at US lead site.
- BB-301 Phase 1b/2a IND/CTA filings planned for Q1 2023; first dosing expected Q2 2023.
- R&D expenses $2.7M, G&A $1.9M for the quarter, both slightly down year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/0001193125-22-281980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312522281980/d412509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer